IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy

By                    

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1325-1336

Spandidos Publications

Access to resources Recommend Favorite

Adjuvant Chemotherapy or Radiotherapy in Cervical Cancer - To the Editor

By Gao X.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 340-341

Elsevier

Access to resources Recommend Favorite

Early breast cancer: Adjuvant chemotherapy or radiotherapy, or both?

By Arriagada Rodrigo  

Acta Oncologica, Vol. 45, Iss. 5, 2006-07 ,pp. : 514-516

Informa Healthcare

Access to resources Recommend Favorite

Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients - a prospective, comparative, non-randomised study

By Fiets W.E.   van Helvoirt R.P.   Nortier J.W.R.   van der Tweel I.   Struikmans H.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1081-1088

Elsevier

Access to resources Recommend Favorite

Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study

By Kim Young-Hoon   Park Chul-Kee   Cho Won   Kim In   Moon Seyoung   Choe Gheeyoung   Park Sung-Hye   Kim Il   Kim Dong   Jung Hee-Won   Lee Min   Bae So   Cha Seung   Kim Chae-Yong  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 503-512

Springer Publishing Company

Access to resources Recommend Favorite